Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Clinical Trial ID NCT02015104

Rank	Title	Journal	Year	PubWeight™‹?›
1	Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.	Clin Cancer Res	2008	1.59
2	Trial Watch: Toll-like receptor agonists in oncological indications.	Oncoimmunology	2014	0.96
3	Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.	J Urol	1988	0.90
4	Antigen-specific vaccines for cancer treatment.	Hum Vaccin Immunother	2014	0.89
5	Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review).	Mol Clin Oncol	2014	0.88
6	Trial Watch: DNA vaccines for cancer therapy.	Oncoimmunology	2014	0.86
7	Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.	Hum Vaccin Immunother	2014	0.81
8	Intravesical therapy for superficial cancer: need for more options.	J Clin Oncol	2002	0.78
9	Oncolytic virotherapy for urological cancers.	Nat Rev Urol	2016	0.76
10	Evolving immunotherapy strategies in urothelial cancer.	Am Soc Clin Oncol Educ Book	2015	0.75
11	Management of carcinoma in situ of the bladder: best practice and recent developments.	Ther Adv Urol	2015	0.75
12	Novel immunotherapeutic approaches to the treatment of urothelial carcinoma.	Ther Adv Urol	2016	0.75
13	Clinical Trials Corner.	Bladder Cancer	2016	0.75
14	Nonmuscle invasive bladder cancer: a primer on immunotherapy.	Cancer Biol Med	2016	0.75